Literature DB >> 11484196

Silica sol-gel for the controlled release of antibiotics. I. Synthesis, characterization, and in vitro release.

S Radin1, P Ducheyne, T Kamplain, B H Tan.   

Abstract

Room temperature processed silica sol-gel (xerogel) was investigated as a novel controlled release carrier of antibiotics (vancomycin). Xerogel characteristics, in vitro release properties, and bactericidal efficacy of the released antibiotic were determined. The xerogel/vancomycin composite showed a long-term sustained release (up to 6 weeks). In addition, bactericidal efficacy of released vancomycin was retained. The kinetics of release and the amount released were dose dependent. The initial, first-order release was followed by a near-zero-order release. The time to transition from the first- to zero-order release increased with vancomycin load (from 2 to 3 weeks with load increase from 2.2 to 11.1 mg/g). Regardless of the load, about 70% of the original vancomycin content was released by the transitional point, and the cumulative release after 6 weeks of immersion was about 90%. This study, combined with other reports documenting biocompatibility and controlled resorbability of the xerogel/drug composite in vivo, suggests that silica xerogel is a promising controlled release material for the treatment of bone infections. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11484196     DOI: 10.1002/1097-4636(200111)57:2<313::aid-jbm1173>3.0.co;2-e

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  18 in total

1.  Nonporous Silica Nanoparticles for Nanomedicine Application.

Authors:  Li Tang; Jianjun Cheng
Journal:  Nano Today       Date:  2013-06       Impact factor: 20.722

2.  Controlled release of small molecules from silica xerogel with limited nanoporosity.

Authors:  Rong Chen; Haibo Qu; Ashwin Agrawal; Shaoyun Guo; Paul Ducheyne
Journal:  J Mater Sci Mater Med       Date:  2012-10-10       Impact factor: 3.896

3.  The inhibition of Staphylococcus epidermidis biofilm formation by vancomycin-modified titanium alloy and implications for the treatment of periprosthetic infection.

Authors:  Valentin Antoci; Christopher S Adams; Javad Parvizi; Helen M Davidson; Russell J Composto; Theresa A Freeman; Eric Wickstrom; Paul Ducheyne; Donald Jungkind; Irving M Shapiro; Noreen J Hickok
Journal:  Biomaterials       Date:  2008-09-23       Impact factor: 12.479

4.  Silica xerogel-chitosan nano-hybrids for use as drug eluting bone replacement.

Authors:  Eun-Jung Lee; Shin-Hee Jun; Hyoun-Ee Kim; Hae-Won Kim; Young-Hag Koh; Jun-Hyeog Jang
Journal:  J Mater Sci Mater Med       Date:  2009-08-06       Impact factor: 3.896

5.  Protein incorporation within Ti scaffold for bone ingrowth using Sol-gel SiO2 as a slow release carrier.

Authors:  Tal Reiner; Shifra Kababya; Irena Gotman
Journal:  J Mater Sci Mater Med       Date:  2007-07-10       Impact factor: 3.896

6.  Nanostructural control of the release of macromolecules from silica sol-gels.

Authors:  Shula Radin; Sanjib Bhattacharyya; Paul Ducheyne
Journal:  Acta Biomater       Date:  2013-05-02       Impact factor: 8.947

7.  Local, Controlled Delivery of Local Anesthetics In Vivo from Polymer - Xerogel Composites.

Authors:  Haibo Qu; Marius C Costache; Saadet Inan; Alan Cowan; David Devore; Paul Ducheyne
Journal:  Pharm Res       Date:  2015-11-10       Impact factor: 4.200

8.  Biomimetic strategies for bone repair and regeneration.

Authors:  Maria G Raucci; Vincenzo Guarino; Luigi Ambrosio
Journal:  J Funct Biomater       Date:  2012-09-20

Review 9.  Mesoporous silica nanoparticles in target drug delivery system: A review.

Authors:  Charu Bharti; Upendra Nagaich; Ashok Kumar Pal; Neha Gulati
Journal:  Int J Pharm Investig       Date:  2015 Jul-Sep

10.  Antibacterial Peptide-Based Gel for Prevention of Medical Implanted-Device Infection.

Authors:  Mihaela Mateescu; Sébastien Baixe; Tony Garnier; Loic Jierry; Vincent Ball; Youssef Haikel; Marie Hélène Metz-Boutigue; Michel Nardin; Pierre Schaaf; Olivier Etienne; Philippe Lavalle
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.